These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 17982704)

  • 1. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats.
    Mendoza S; Noa M; Mas R; Mendoza N
    Drugs Exp Clin Res; 2005; 31(5-6):181-91. PubMed ID: 16425974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
    Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
    Woo JT; Kasai S; Stern PH; Nagai K
    J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease.
    Wu B; Elmariah S; Kaplan FS; Cheng G; Mohler ER
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):592-7. PubMed ID: 15618546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
    Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
    Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation.
    Oxlund H; Andreassen TT
    Bone; 2004 Apr; 34(4):609-18. PubMed ID: 15050891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
    Idris AI; Landao-Bassonga E; Ralston SH
    Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statins and osteoporosis].
    Svejda P
    Vnitr Lek; 2006 Dec; 52(12):1190-3. PubMed ID: 17299913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
    Luan Z; Chase AJ; Newby AC
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and osteoporosis: new role for old drugs.
    Jadhav SB; Jain GK
    J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins, fracture risk, and bone remodeling.
    Luisetto G; Camozzi V
    J Endocrinol Invest; 2009; 32(4 Suppl):32-7. PubMed ID: 19724164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.